Form 4: Director Corsee Sanders Sells BeOne Medicines Shares

Director Corsee Sanders disposed of 212 American Depositary Shares of BeOne Medicines Ltd. to satisfy tax withholding obligations.

Summary

• Director Corsee Sanders sold 212 American Depositary Shares (ADS) of BeOne Medicines Ltd. (ONC).
• The transaction occurred on May 22, 2026, at a price of $309.5896 per share.
• The sale was executed to satisfy mandatory tax withholding requirements related to the vesting of restricted share units.
• Following the transaction, the director retains 54,470 Ordinary Shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was purely administrative to satisfy tax obligations rather than a strategic divestment.

Positives

• The transaction was a mandatory tax-related sale rather than a discretionary divestment, indicating continued alignment with company interests.

Negatives

• Reduction in direct share ownership by a member of the board of directors.

Risks

• Vesting of restricted share units is contingent upon continued service as a director.
• Potential for accelerated vesting upon a change in control or specific termination events.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of an insider transaction.

Management Comments

• The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement.

Industry Context

StockSavvy.ai notes that mandatory tax-related sales by directors are standard corporate governance practices and generally do not signal a change in sentiment regarding the company's long-term prospects.

Comparison to Industry Standards

• The use of mandatory sell-to-cover transactions for tax obligations is a standard practice among publicly traded biotechnology and pharmaceutical companies to manage equity compensation tax liabilities.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax-related sell-to-cover event.

Next Steps

• Future vesting of remaining restricted share units subject to continued board service.

Key Dates

Keywords

BeOne Medicines, ONC, Insider Trading, Form 4, SEC Filing, Director Transaction